Pre-clinical combination of a PARP inhibitor, talazoparib, and carboplatin in triple-negative breast cancer.

被引：0
作者：
Cotte, Alexia [1 ]
Beniey, Michele [1 ]
Haque, Takrima [2 ]
Bechir, Nelly [2 ]
Hubert, Audrey [1 ]
Diallo, Korotoum W. [1 ]
Tran-Thanh, Danh [2 ]
Hassan, Saima N. [1 ]
机构：
[1] Univ Montreal, Ctr Rech Univ Montreal CRCHUM, Montreal, PQ H3C 3J7, Canada
[2] Ctr Rech Univ Montreal CRCHUM, Montreal, PQ, Canada
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1066
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor
    Song, Dandan
    He, Huan
    Sinha, Indranil
    Hases, Linnea
    Yan, Feifei
    Archer, Amena
    Haldosen, Lars-Arne
    Zhao, Chunyan
    Williams, Cecilia
    CANCER LETTERS, 2021, 506 : 23 - 34
  • [22] Cell Cycle Effects of Iniparib, a PARP Inhibitor, in Combination with Gemcitabine and Carboplatin in the MDA-MB-468(-) Triple-Negative Breast Cancer (TNBC) Cell Line
    Ossovskaya, V.
    Lim, C-U
    Schools, G.
    Kalurupalle, S.
    Roninson, I. B.
    Broude, E.
    CANCER RESEARCH, 2010, 70
  • [23] FXR Agonism with Bile Acid Mimetic Reduces Pre-Clinical Triple-Negative Breast Cancer Burden
    Joseph, Sydney C.
    Eugin Simon, Samson
    Bohm, Margaret S.
    Kim, Minjeong
    Pye, Madeline E.
    Simmons, Boston W.
    Graves, Dillon G.
    Thomas-Gooch, Stacey M.
    Tanveer, Ubaid A.
    Holt, Jeremiah R.
    Ponnusamy, Suriyan
    Sipe, Laura M.
    Hayes, D. Neil
    Cook, Katherine L.
    Narayanan, Ramesh
    Pierre, Joseph F.
    Makowski, Liza
    CANCERS, 2024, 16 (07)
  • [24] A Review of Metabolic Targets of Anticancer Nutrients and Nutraceuticals in Pre-Clinical Models of Triple-Negative Breast Cancer
    Wiggs, Alleigh
    Molina, Sabrina
    Sumner, Susan J.
    Rushing, Blake R.
    NUTRIENTS, 2022, 14 (10)
  • [25] Proteomic analysis of talazoparib resistance in triple-negative breast cancer cells
    Guney Eskiler, Gamze
    Yanar, Sevinc
    Akpinar, Gurler
    Kasap, Murat
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2021, 35 (03)
  • [26] Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy
    Chia, J. W.
    Ang, P.
    See, H.
    Wong, Z.
    Soh, L.
    Yap, Y.
    Wong, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Epigenetic heterogeneity in triple-negative breast cancer.
    Maruyama, Reo
    Yang, Liying
    Kumegawa, Kohei
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 29 - 30
  • [28] Combination chemotherapy with docetaxel and carboplatin in triple-negative breast cancer: a single institution experience
    Kurbacher, C. M.
    Kurbacher, J. A.
    Braun, K.
    Mehra, S.
    Schweitzer, C.
    Arenz, P. N.
    ONKOLOGIE, 2010, 33 : 29 - 29
  • [29] Chronobiological assessment of triple-negative breast cancer.
    Revazishvili, Pati
    Tavartkiladze, Alexandre
    Tavartkiladze, Levan
    Sordia, Teimuraz
    Gvajaia, Ani
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Combination benefit between PARP inhibitor niraparib and angiogenesis inhibitors in PDX models of triple-negative breast cancer (TNBC).
    Zhou, Yinghui
    Wang, Sarah
    Mikule, Keith
    Ramaswamy, Sridhar
    Hanke, Jeffrey
    Wang, Jing Yu
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 32 - 33
12345